Investigating how diabetes affects treatment outcomes in lung cancer patients on immunotherapy
Effect of Diabetes Mellitus on Outcomes and Response Rate in Patients With Advanced NSCLC on Immunotherapy
This study looks at how having diabetes affects the success of immunotherapy treatments in lung cancer patients to see if it changes their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Assiut) |
| Trial ID | NCT06100796 on ClinicalTrials.gov |
What this trial studies
This observational study retrospectively examines the impact of diabetes mellitus (DM) on the response rates and outcomes of patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI) over the past five years. It aims to clarify the relationship between DM and treatment efficacy in the context of immunotherapy, which has significantly improved survival rates for NSCLC patients. By analyzing data from patients treated with pembrolizumab, the study seeks to identify potential predictors of response to ICI in this population. The findings could help tailor treatment strategies for lung cancer patients with comorbid diabetes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with advanced non-small cell lung cancer who have received immune checkpoint inhibitors.
Not a fit: Patients without advanced non-small cell lung cancer or those who have not received immune checkpoint inhibitors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for lung cancer patients with diabetes, enhancing their response to immunotherapy.
How similar studies have performed: While the relationship between diabetes and cancer treatment outcomes is an area of ongoing research, this specific investigation into the effects of DM on immunotherapy response in NSCLC is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All consecutive patients with advanced Non Small Cell Lung Cancer who received Immune Check Inhibitors alone or in combination with chemotherapy, either as first line or as a subsequent line Exclusion Criteria: * None
Where this trial is running
Assiut
- Assiut university — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Momen Eltaher
- Email: drmeem@gmail.com
- Phone: +96893981742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.